Dose-Intensive Regimens Appear Promising in Hodgkin’s, NHL

Article

SAN DIEGO--The longest follow-up studies to date on dose-intensive therapy with peripheral blood stem cell or bone marrow support in patients with Hodgkin’s disease or non-Hodgkin’s lymphoma (NHL) show some promising results with specific drug regimens.

SAN DIEGO--The longest follow-up studies to date on dose-intensive therapy with peripheral blood stem cell or bone marrow support in patients with Hodgkin’s disease or non-Hodgkin’s lymphoma (NHL) show some promising results with specific drug regimens.

Roger Herzig, MD, director of the University of Louisville’s blood and marrow transplant program, presented the data from the North American Marrow Transplant Group (NAMTG) at the Sixth International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation, sponsored by the University of San Diego.

"We suspected that these regimens could lead to long-term cures, and now we have supporting data," Dr. Herzig commented. "Nearly half of the Hodgkin’s disease patients who were treated with transplant are alive and well, and the malignant lymphoma patients who had a complete response after transplant or who went into the transplant in complete response have probably a 40% cure rate."

The Hodgkin’s disease study was conducted between January 1987 and June 1993. The 131 patients, who had all failed conventional therapy, were treated with a single regimen using continuous infusion of CBVi (cyclophosphamide, car-mustine, etoposite). Their median age was 27 years.

Of these patients, 112 (85%) responded, and 91 (70%) had a complete response. Notably, the median follow-up for these patients is 5 years (range, 3 to 10 years), with 44% survival (95% CI, 33% to 51%). The NAMTG researchers did not detect any patient characteristics that predicted a poor outcome.

Malignant Lymphoma Study

In the study on malignant lymphoma, 108 patients were treated between 1987 and 1994. All of these patients--71 men and 37 women--received total body irradiation, as well as etoposide and cyclophosphamide. Among these patients, 83% responded to the treatment; 44 patients have died of recurrent or progressive disease.

In this study, experiencing a complete response and having a high Karnofsky score were both associated with better outcomes.

"The patients who achieved a complete remission had an overall long-term survival rate of about 40% to 50%, which is quite good," Dr. Herzig observed. While B symptoms have been associated with poorer outcomes in the past, the present analysis did not detect a difference.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.